Association of aspirin resistance with increased stroke severity and infarct size

JAMA Neurology

Volumn 70, Issue 2, 2013, Pages 208-213

  Zheng, Amy S Y ^a   Churilov, Leonid ^a,c   Colley, Ruth E ^a   Goh, Christine ^a,b   Davis, Stephen M ^a,b   Yan, Bernard ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID;

AGED; ALBERTA STROKE PROGRAM EARLY CT SCORE; ARTICLE; AUSTRALIA; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; MALE; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NERVOUS SYSTEM PARAMETERS; NEUROIMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCORING SYSTEM; STROKE INFARCT SIZE; STROKE PATIENT; VERIFYNOW SYSTEM;

EID: 84874055141     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2013.601     Document Type: Article

References (42)

1. Lees KR, Bluhmki E, von Kummer R, et al; ECASS, ATLANTIS, NINDS and EPITHET rt-PA Study Group. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2010;375(9727):1695-1703.
2. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet. 1997;349(9065):1569-1581.
3. Chen ZM, Sandercock P, Pan HC, et al. Indications for early aspirin use in acute ischemic stroke: a combined analysis of 40 000 randomized patients from the Chinese acute stroke trial and the international stroke trial. on behalf of the CAST and IST collaborative groups. Stroke. 2000;31(6):1240-1249.
4. Wilterdink JL, Bendixen B, Adams HP Jr, Woolson RF, Clarke WR, Hansen MD. Effect of prior aspirin use on stroke severity in the trial of Org 10172 in acute stroke treatment (TOAST). Stroke. 2001;32(12):2836-2840.
5. Sanossian N, Saver JL, Rajajee V, et al. Premorbid antiplatelet use and ischemic stroke outcomes. Neurology. 2006;66(3):319-323.
6. Zheng Z, Schwab S, Grau A, Berger C. Neuroprotection by early and delayed treatment of acute stroke with high dose aspirin. Brain Res. 2007;1186:275-280.
7. Ovbiagele B, Buck BH, Liebeskind DS, et al. Prior antiplatelet use and infarct volume in ischemic stroke. J Neurol Sci. 2008;264(1-2):140-144.
8. Loll PJ, Picot D, Garavito RM. The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nat Struct Biol. 1995;2(8):637-643.
9. Awtry EH, Loscalzo J. Aspirin. Circulation. 2000;101(10):1206-1218.
10. Huang ZS, Teng CM, Lee TK, Shun CT, Wang CY. Combined use of aspirin and heparin inhibits in vivo acute carotid thrombosis. Stroke. 1993;24(6):829-836, discussion 837-838.
11. Joseph R, Han E, Tsering C, Grunfeld S, Welch KM. Platelet activity and stroke severity. J Neurol Sci. 1992;108(1):1-6.
12. Kuhn W, Müller T, Bttner T, Gerlach M. Aspirin as a free radical scavenger: consequences for therapy of cerebrovascular ischemia. Stroke. 1995;26(10):1959-1960.
13. Grilli M, Pizzi M, Memo M, Spano P. Neuroprotection by aspirin and sodium salicylate through blockade of NF-kappaB activation. Science. 1996;274(5291): 1383-1385.
14. Hankey GJ, Eikelboom JW. Aspirin resistance. BMJ. 2004;328(7438):477-479.
15. Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet. 2006;367(9510):606- 617.
16. Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ. 2008; 336(7637):195-198.
17. Bennett D, Yan B, Macgregor L, Eccleston D, Davis SM. A pilot study of resistance to aspirin in stroke patients. J Clin Neurosci. 2008;15(11):1204- 1209.
18. Grotemeyer KH, Scharafinski HW, Husstedt IW. Two-year follow-up of aspirin responder and aspirin non responder: a pilot-study including 180 post-stroke patients. Thromb Res. 1993;71(5):397-403.
19. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation. 2002;105(14):1650-1655.
20. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol. 2003;41(6):961-965.
21. Mason PJ, Jacobs AK, Freedman JE. Aspirin resistance and atherothrombotic disease. J Am Coll Cardiol. 2005;46(6):986-993.
22. Schwammenthal Y, Tsabari R, Shenkman B, et al. Aspirin responsiveness in acute brain ischaemia: association with stroke severity and clinical outcome. Cerebrovasc Dis. 2008;25(4):355-361.
23. Englyst NA, Horsfield G, Kwan J, Byrne CD. Aspirin resistance is more common in lacunar strokes than embolic strokes and is related to stroke severity. J Cereb Blood Flow Metab. 2008;28(6):1196-1203.
24. Pexman JHW, Barber PA, Hill MD, et al. Use of the Alberta Stroke Program Early CT Score (ASPECTS) for assessing CT scans in patients with acute stroke. AJNR Am J Neuroradiol. 2001;22(8):1534-1542.
25. Brott T, Adams HP Jr, Olinger CP, et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke. 1989;20(7):864-870.
26. Barber PA, Demchuk AM, Zhang J, Buchan AM. Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy: ASPECTS Study Group. Alberta Stroke Programme Early CT Score. Lancet. 2000;355(9216):1670-1674.
27. Coleman JL, Wang JC, Simon DI. Determination of individual response to aspirin therapy using the Accumetrics Ultegra RPFA-ASA system. Point of Care. 2004; 3:77-82. doi:10.1097/01.poc.0000127153.41926.ba.
28. van Werkum JW, Harmsze AM, Elsenberg EHAM, Bouman HJ, ten Berg JM, Hackeng CM. The use of the VerifyNow system to monitor antiplatelet therapy: a review of the current evidence. Platelets. 2008;19(7):479-488.
29. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71-86.
30. Gaspoz JM, Coxson PG, Goldman PA, et al. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. N Engl J Med. 2002;346(23):1800-1806.
31. Coma-Canella I, Velasco A, Castano S. Prevalence of aspirin resistance measured by PFA-100. Int J Cardiol. 2005;101(1):71-76.
32. Cotter G, Shemesh E, Zehavi M, et al. Lack of aspirin effect: aspirin resistance or resistance to taking aspirin? Am Heart J. 2004;147(2):293-300.
33. Bushnell CD, Zimmer LO, Pan W, et al; Adherence Evaluation After Ischemic Stroke-Longitudinal Investigators. Persistence with stroke prevention medications 3 months after hospitalization. Arch Neurol. 2010;67(12):1456-1463.
34. Goodman T, Ferro A, Sharma P. Pharmacogenetics of aspirin resistance: a comprehensive systematic review. Br J Clin Pharmacol. 2008;66(2):222-232.
35. Gum PA, Kottke-Marchant K, Poggio ED, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol. 2001;88(3): 230-235.
36. McCabe DJ, Harrison P, Mackie IJ, et al. Assessment of the antiplatelet effects of low to medium dose aspirin in the early and late phases after ischaemic stroke and TIA. Platelets. 2005;16(5):269-280.
37. Lee PY, Chen WH, Ng W, et al. Low-dose aspirin increases aspirin resistance in patients with coronary artery disease. Am J Med. 2005;118(7):723-727.
38. Kolominsky-Rabas PL, Weber M, Gefeller O, Neundoerfer B, Heuschmann PU. Epidemiology of ischemic stroke subtypes according to TOAST criteria: incidence, recurrence, and long-term survival in ischemic stroke subtypes. a population-based study. Stroke. 2001;32(12):2735-2740.
39. Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med. 2008;359 (9):938-949.
40. Hallenbeck JM, Furlow TW Jr. Prostaglandin I2 and indomethacin prevent impairment of post-ischemic brain reperfusion in the dog. Stroke. 1979;10(6): 629-637.
41. Hung J, Lam JY, Lacoste L, Letchacovski G. Cigarette smoking acutely increases platelet thrombus formation in patients with coronary artery disease taking aspirin. Circulation. 1995;92(9):2432-2436.
42. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet. 1993;342(8882):1255-1262.